Moral Panic: Hayley Williams, My Chemical Romance and the rest of the week’s emo news in brief – Louder

Over the last few years, the 00s emo revival has been snowballing. With comeback tours, reformations, emo nights and new artists adopting the sound, its now somehow bigger than ever. In the last few months, the quiet hum of emos comeback has grown to a scream, and its here to stay. 2020 is the new 2005, so in this fortnightly column, Marianne Eloise, whos been covering the revival since 2016, will round up (some) of the near-daily emo news: from new shows to new songs to cryptic clues.

Its been another huge two weeks for the 00s emo revival, and naturally, My Chemical Romance have been pretty much dominating the entire conversation. With their US tour being announced, on sale and sold out within a matter of days, US MCR fans have been completely bankrupted in the last fortnight.

That also means that some of the smaller news has been swiftly forgotten in the midst of MCR mania (it really is 2006!). Hayley Williams has also been incredibly busy, releasing two new songs, debuting the cover of her album, and putting us all through an emotional wringer.

Here are some of the highlights from a very emo fortnight:

While The All American Rejects havent strictly gone anywhere, they have teased that they might throw their hat in the nostalgia ring. When a fan tweeted that their 2005 album Move Along is an underrated powerhouse, they quote tweeted him to say, Cheers bud, shes turning 15 this year... think we are gonna do a real tribute for it, sound like a plan? A lot of fans got very excited very quickly, offering to empty their bank accounts if the band do a full tour, but they havent yet announced anything officially.

While The Used and My Chemical Romances relationship has been at times fraught, the two bands have a long history. A lot of fans just want to see them working together again specifically, with The Used supporting on the comeback tour.

It looks like it might just be a reality. On their current tour, Bert McCracken joked a few separate times that The Used could be supporting MCR, at one point saying, You can probably catch us on tour with My Chemical Romance in the fall. Well see. he later said, Im not saying Im joking. Come on, you know me, Im a kidder. but who knows? Maybe its a double bluff.

On January 29, MCR dropped another cryptic video entitled A Summoning. At 13 minutes long, the video announced a US tour while stirring up nostalgia in their oldest fans. Its jam packed with references to key moments in MCR history, like Im Not Okay, The Black Parade era, dead friends and colleagues, Helena, Killjoys, Life On The Murder Scene... etc. Its full of the cult-y imagery of the previous teaser videos, and at the end, announces the US tour dates. Naturally, the dates sold out in minutes, with additional shows being added in LA and the extremely high resale prices becoming very controversial. Still, its all just testament to how loved My Chemical Romance are in 2020. Their fans are not to be reckoned with. Plus, many believe that the sounds heard in A Summoning will be part of new music.

As The Format split in 2008, singer Nate Ruess is probably better known by many as the singer of pop band Fun., which he formed with Jack Antonoff. But The Format were pretty formative for a lot of baby emos, and after years of silence, this week they surprised everyone with an impromptu acoustic performance at a screening of their 2007 concert film Live At The Mayan Theatre. They havent announced new music just yet, but if youre in the US, they will be playing five shows in March and April.

After releasing the vicious, beautiful song Simmer a few weeks ago, Hayley Williams gifted fans with some more news and music. She teased a new song with a video entitled Simmer Interlude that saw Williams-as-monster wrapping her human self in a cocoon. She also tweeted, theres more to the story. Its almost never what you think.

The song, Leave It Alone, is far more subdued and less unnerving than Simmer. A heartfelt rumination on grief and loss, it relies primarily on strings and Williams voice. The video shows her waking in a cocoon as a scaly, butterfly-esque creature in Bjrk-like costume and makeup singing, 'Now that I finally wanna live/the ones I love are dying'.

We then see her emerge from the cocoon, and human Hayley walks around the woods, where we also see a body under a sheet. It marks the continuation of an incredibly raw and emotionally generous era for Williams, cemented by her debuting the cover for Petals For Armor, which features her makeup-free looking at the camera. Not keen to let her fans rest for a second, on February 6, Hayley released an eerie video for more upbeat song Cinnamon, a poppy testament to being home alone and free. And then she released the first half of her album, with two brand new tracks! She never stops!

That's all for this fortnight check back in two weeks' time for the latest in the world's emo revival news

See original here:
Moral Panic: Hayley Williams, My Chemical Romance and the rest of the week's emo news in brief - Louder

In My Country, Sex Is Still Taboo, and Not Talking About It Has Made Things Worse – Yahoo Lifestyle

Fashionable, pregnant teenager leaning on a grungy brick wall. Shot with room for text on right.

When I was in fifth grade back home in the Dominican Republic, I had "the talk" with my mom. It might seem a little young, but our school was teaching us about human reproduction, and they had told the parents that they would address the biological part of it, but the parents had to sit down with us and go over the fact that people didn't necessarily do it for human reproduction purposes.

For me, the talk was very positive. My mom has always been very straightforward and has made sure that I trust her enough to reach out to her with any questions or concerns. But I knew that wasn't the case with everyone. And as I grew older and actually hit puberty, the chat around sex became all about abstinence rather than "this is how you can protect yourself."

Let's be honest: if you tell any teenager that they're not allowed to do something, they will want to do it even more. But then, in a country like the Dominican Republic, you also had the church's influence dictating how people - particularly women - should live their lives.

The church and the state are pretty much one entity - there's no real separation. So, when it comes to issues such as allowing women to choose what to do with their bodies, or even teaching sex ed in schools, there's an automatic push against it because "that's not how God wanted it."

They vilify sex, making it seem like the ultimate sin when done outside of the "sacred bond of marriage." They limit access to information to vulnerable people, the ones who only have access to a church in their community, and as a result, we have a teenage pregnancy crisis.

Human Rights Watch reported in a study that the Dominican Republic has the highest adolescent fertility rate of all of the countries in Latin America and the Caribbean, according to the Pan American Health Organization (PAHO).

"While some adolescent pregnancies are planned and wanted at the time they occur, many are not. The total ban on abortion in the Dominican Republic means adolescent girls facing unwanted pregnancies must choose between clandestine and often risky abortions or the lifelong consequences of having a child against their wishes."

The study goes on to list the consequences of this crisis, starting with serious health risks not only for the mother but also the baby, difficulty for the expecting mother to continue her education - despite a law that prohibits expulsion of pregnant girls from school - which then cuts back even more on her chances for a better life for her and her child. In most cases, the girls end up trapped in a never-ending poverty cycle, which then traps their babies when they're born. And it doesn't help that in many parts of the DR, there's no place girls can gain access to confidential, nonstigmatizing, adolescent-friendly sexual and reproductive health services.

"The Dominican Republic is one of few countries in Latin America and the Caribbean where abortion is criminalized and prohibited in all circumstances, even for women and girls who become pregnant from rape or incest, whose lives are endangered by pregnancy, or who are carrying pregnancies that are not viable, meaning the fetus will not survive outside the womb," The Human Rights Watch study continued.

Girls, particularly those from poor and rural communities, suffer the consequences of these policy failures most profoundly, and that's why it's so important to provide information, talk about sexual and reproductive health, foment sexual education in schools, expand health services and providers who aren't judgmental, decriminalize abortion, and give girls and women the option to safely end their pregnancies.

See original here:
In My Country, Sex Is Still Taboo, and Not Talking About It Has Made Things Worse - Yahoo Lifestyle

End procreation to save Earth, says ARU author in The Ahuman Manifesto – Cambridge Independent

Dr Patricia MacCormack, author of The Ahuman Manifesto, is professor of continental philosophy at Anglia Ruskin University

An Anglia Ruskin University (ARU) author believes she has solved the problem of over-population by allowing humanity to become extinct through ending procreation.

Dr Patricia MacCormack, professor of continental philosophy at Anglia Ruskin University (ARU), has even invented a new term for a post-human world: the ahuman will avoid ecological collapse by going beyond binaries of human and not human, according to The Ahuman Manifesto which is launched in Cambridge this week.

Far from advocating mass death, genocide or eugenics, my manifesto is antinatalist, says Dr MacCormack. It boycotts human reproduction due to the damage humans have perpetrated on the Earth and its other inhabitants.

The manifesto simply asks that humans no longer reproduce no life is lost, no being is mourned. If we no longer reproduce, we can care for all inhabitants already here, human and non-human, as well as care for the Earth itself by mitigating the damage already caused. Its an activism of care.

It questions the value of human exceptionalism, asking are humans really the best forms of life, or should we dismantle our understanding of life as a hierarchy for a more ecological, interconnected scheme of living things?

The fundamental realignment of our future residence on planet Earth means, eventually, self-extinction, but its also intended to be joyful.

My manifesto sees a joy in living the lives we have and developing strategies of care for the Earths next chapter, she says. This is an Earth thats allowed to thrive not in spite of but because of the reduction and eventual absence of humans.

Dr MacCormack suggests that there is an ideological commitment to understanding having children as familial eugenics, ie my DNA is more important than anyone elses is the premise of having children. It is this superiority complex, unchallenged, which is leading us to our demise.

Ahuman is a term I invented which acknowledges we have human residue and accountability but shows we want to refuse human privilege and human-made hierarchies of life, she told the Cambridge Independent. It is a space between human and animal, human and post-human, human and earth. It may be the traitor to the species or the apocalypse of anthropocentrism.

As we wind the clock down, suggests Dr MacCormack, society should allow adoption to be easier, and end the concept of legal and illegal children.

The sensational new term actively embraces issues like human extinction, vegan abolition, atheist occultism, death studies, a refusal of identity politics, deep ecology, and the apocalypse as an optimistic beginning (albeit for other forms of life than humanity).

So how long did it take the book to write?

It took a lifetime, says Dr MacCormack, but the current political global climate quickened its necessity.

The Ahuman Manifesto is published by Bloomsbury at 21.99.

Read this article:
End procreation to save Earth, says ARU author in The Ahuman Manifesto - Cambridge Independent

The biology, function, and biomedical applications of exosomes – Science Magazine

Clinical uses of cellular communication

Exosomes are a type of extracellular vesicle that contain constituents (protein, DNA, and RNA) of the cells that secrete them. They are taken up by distant cells, where they can affect cell function and behavior. Intercellular communication through exosomes seems to be involved in the pathogenesis of various disorders, including cancer, neurodegeneration, and inflammatory diseases. In a Review, Kalluri and LeBleu discuss the biogenesis and function of exosomes in disease, highlighting areas where more research is needed. They also discuss the potential clinical applications of exosome profiling for diagnostics and exosome-mediated delivery of therapeutics to target disease cells.

Science, this issue p. eaau6977

All cells, prokaryotes and eukaryotes, release extracellular vesicles (EVs) as part of their normal physiology and during acquired abnormalities. EVs can be broadly divided into two categories, ectosomes and exosomes. Ectosomes are vesicles that pinch off the surface of the plasma membrane via outward budding, and include microvesicles, microparticles, and large vesicles in the size range of ~50 nm to 1 m in diameter. Exosomes are EVs with a size range of ~40 to 160 nm (average ~100 nm) in diameter with an endosomal origin. Sequential invagination of the plasma membrane ultimately results in the formation of multivesicular bodies, which can intersect with other intracellular vesicles and organelles, contributing to diversity in the constituents of exosomes. Depending on the cell of origin, EVs, including exosomes, can contain many constituents of a cell, including DNA, RNA, lipids, metabolites, and cytosolic and cell-surface proteins. The physiological purpose of generating exosomes remains largely unknown and needs investigation. One speculated role is that exosomes likely remove excess and/or unnecessary constituents from cells to maintain cellular homeostasis. Recent studies reviewed here also indicate a functional, targeted, mechanism-driven accumulation of specific cellular components in exosomes, suggesting that they have a role in regulating intercellular communication.

Exosomes are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous systemrelated diseases, and cancer progression. Proteins, metabolites, and nucleic acids delivered by exosomes into recipient cells effectively alter their biological response. Such exosome-mediated responses can be disease promoting or restraining. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer. Exosomes can be engineered to deliver diverse therapeutic payloads, including short interfering RNAs, antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. The lipid and protein composition of exosomes can affect their pharmacokinetic properties, and their natural constituents may play a role in enhanced bioavailability and in minimizing adverse reactions. In addition to their therapeutic potential, exosomes also have the potential to aid in disease diagnosis. They have been reported in all biological fluids, and the composition of the complex cargo of exosomes is readily accessible via sampling of biological fluids (liquid biopsies). Exosome-based liquid biopsy highlights their potential utility in diagnosis and determining the prognosis of patients with cancer and other diseases. Disease progression and response to therapy may also be ascertained by a multicomponent analysis of exosomes.

The study of exosomes is an active area of research. Ongoing technological and experimental advances are likely to yield valuable information regarding their heterogeneity and biological function(s), as well as enhance our ability to harness their therapeutic and diagnostic potential. As we develop more standardized purification and analytical procedures for the study of exosomes, this will likely reveal their functional heterogeneity. Nonetheless, functional readouts using EVs enriched for exosomes have already provided new insights into their contribution to various diseases. New genetic mouse models with the ability for de novo or induced generation of cell-specific exosomes in health and disease will likely show the causal role of exosomes in cell-to-cell communication locally and between organs. Whether exosome generation and content change with age needs investigation, and such information could offer new insights into tissue senescence, organ deterioration, and programmed or premature aging. Whether EVs and/or exosomes preceded the first emergence of the single-cell organism on the planet is tempting to speculate, and focused bioelectric and biochemical experiments in the future could reveal their cell-independent biological functions. Single-exosome identification and isolation and cryoelectron microscopy analyses have the potential to substantially improve our understanding of the basic biology of exosomes and their use in applied science and technology. Such knowledge will inform the therapeutic potential of exosomes for various diseases, including cancer and neurodegenerative diseases.

Exosomes are extracellular vesicles generated by all cells and they carry nucleic acids, proteins, lipids, and metabolites. They are mediators of near and long-distance intercellular communication in health and disease and affect various aspects of cell biology.

The study of extracellular vesicles (EVs) has the potential to identify unknown cellular and molecular mechanisms in intercellular communication and in organ homeostasis and disease. Exosomes, with an average diameter of ~100 nanometers, are a subset of EVs. The biogenesis of exosomes involves their origin in endosomes, and subsequent interactions with other intracellular vesicles and organelles generate the final content of the exosomes. Their diverse constituents include nucleic acids, proteins, lipids, amino acids, and metabolites, which can reflect their cell of origin. In various diseases, exosomes offer a window into altered cellular or tissue states, and their detection in biological fluids potentially offers a multicomponent diagnostic readout. The efficient exchange of cellular components through exosomes can inform their applied use in designing exosome-based therapeutics.

Continued here:
The biology, function, and biomedical applications of exosomes - Science Magazine

R0: How scientists quantify the intensity of an outbreak like coronavirus and its pandemic potential – The Conversation US

If you saw the 2011 movie Contagion, about a worldwide pandemic of a new virus, then youve heard the term R0.

Pronounced R naught, this isnt just jargon made up in Hollywood. It represents an important concept in epidemiology and is a crucial part of public health planning during an outbreak, like the current coronavirus epidemic spreading outward from China.

Scientists use R0 the reproduction number to describe the intensity of an infectious disease outbreak. R0 estimates have been an important part of characterizing pandemics or large publicized outbreaks, including the 2003 SARS pandemic, the 2009 H1N1 Influenza pandemic and the 2014 Ebola epidemic in West Africa.

The formal definition of a diseases R0 is the number of cases, on average, an infected person will cause during their infectious period.

The term is used in two different ways.

The basic reproduction number represents the maximum epidemic potential of a pathogen. It describes what would happen if an infectious person were to enter a fully susceptible community, and therefore is an estimate based on an idealized scenario.

The effective reproduction number depends on the populations current susceptibility. This measure of transmission potential is likely lower than the basic reproduction number, based on factors like whether some of the people are vaccinated against the disease, or whether some people have immunity due to prior exposure with the pathogen. Therefore, the effective R0 changes over time and is an estimate based on a more realistic situation within the population.

Its important to realize that both the basic and effective R0 are situation-dependent. Its affected by the properties of the pathogen, such as how infectious it is. Its affected by the host population for instance, how susceptible people are due to nutritional status or other illnesses that may compromise ones immune system. And its affected by the environment, including things like demographics, socioeconomic and climatic factors.

For example, R0 for measles ranges from 12 to 18, depending on factors like population density and life expectancy. This is a large R0, mainly because the measles virus is highly infectious.

On the other hand, the influenza virus is less infectious, with its R0 ranging from 2 to 3. Influenza, therefore, does not cause the same explosive outbreaks as measles, but it persists due to its ability to mutate and evade the human immune system.

Demographer Alfred Lotka proposed the reproduction number in the 1920s, as a measure of the rate of reproduction in a given population.

In the 1950s, epidemiologist George MacDonald suggested using it to describe the transmission potential of malaria. He proposed that, if R0 is less than 1, the disease will die out in a population, because on average an infectious person will transmit to fewer than one other susceptible person. On the other hand, if R0 is greater than 1, the disease will spread.

When public health agencies are figuring out how to deal with an outbreak, they are trying to bring R0 down to less than 1. This is tough for diseases like measles that have a high R0. It is especially challenging for measles in densely populated regions like India and China, where R0 is higher, compared to places where people are more spread out.

For the SARS pandemic in 2003, scientists estimated the original R0 to be around 2.75. A month or two later, the effective R0 dropped below 1, thanks to the tremendous effort that went into intervention strategies, including isolation and quarantine activities.

However, the pandemic continued. While on average, an infectious person transmitted to fewer than one susceptible individual, occasionally one person transmitted to tens or even hundreds of other cases. This phenomenon is called super spreading. Officials documented super spreader events a number of times during the SARS epidemic in Singapore, Hong Kong and Beijing.

A number of groups have estimated R0 for this new coronavirus. The Imperial College group has estimated R0 to be somewhere between 1.5 and 3.5. Scientists from the Chinese Academy of Sciences Institute of Automation and the University of Chinese Academy of Sciences have estimated R0 to be much higher, at 4.08.

These differences are not surprising; theres uncertainty about many of the factors go into estimating R0, such as in estimating the number of cases, especially early on in an outbreak.

Based on these current estimates, projections of the future number of cases of coronavirus are fraught with high levels of uncertainty and will likely be somewhat inaccurate.

The difficulties arise for a number of reasons.

First, the basic properties of this viral pathogen like the infectious period are as yet unknown.

Second, researchers dont know how many mild cases or infections that dont result in symptoms have been missed by surveillance but nevertheless are spreading the disease.

Third, the majority of people who come down with this new coronavirus do recover, and are likely then immune to coming down with it again. Its unclear how the changing susceptibility of the population will affect the future spread of infection. This is especially important in Wuhan, the origin of the epidemic.

Finally, and likely the most important reason, no one knows the future impacts of current disease control measures. Epidemiologists current estimates of R0 say nothing about how measures such as isolation or quarantine efforts will influence the virus future spread.

[ Youre smart and curious about the world. So are The Conversations authors and editors. You can get our highlights each weekend. ]

View post:
R0: How scientists quantify the intensity of an outbreak like coronavirus and its pandemic potential - The Conversation US

Misinformation on the coronavirus might be the most contagious thing about it – The Guardian

When reports of a new coronavirus emerged last month, I speculated with fellow epidemiologists about what the media might end up naming the infection. None of us would have guessed that within a week or so a theory would be circulating that coronavirus was a new kind of snake flu mostly because its unlikely the virus originated in snakes, and its not flu.

So where did the snakes come from? The culprit was a widely shared scientific paper, which speculated that the new virus had genetic characteristics and implicated snakes as the source. Leading geneticists were quick to point out that the results werent convincing, and that bats were still the likely suspects. However, that didnt stop snake flu from going viral. Other misinformation about coronavirus has rippled across the internet in recent weeks. From claims the virus is part-HIV to conspiracy theories about bioweapons and reports suggesting the virus was linked to people eating bat soup, stories sparking fear seem to have overtaken the outbreak in real life. Is misinformation really more contagious than the virus itself?

What is the virus causing illness in Wuhan?

It is a member of the coronavirus family that has never been encountered before. Like other coronaviruses, it has come from animals. Many of those initially infected either worked or frequently shopped in the Huanan seafood wholesale market in the centre of the Chinese city.

What other coronaviruses have there been?

New and troubling viruses usually originate in animal hosts. Ebola and flu are other examples severe acute respiratory syndrome (Sars) and Middle Eastern respiratory syndrome (Mers) are both caused by coronaviruses that came from animals.

What are the symptoms of the Wuhan coronavirus?

The virus causespneumonia. Those who have fallen ill are reported to suffer coughs, fever and breathing difficulties. In severe cases there can be organ failure. As this is viral pneumonia, antibiotics are of no use. The antiviral drugs we have against flu will not work. If people are admitted to hospital, they may get support for their lungs and other organs as well as fluids. Recovery will depend on the strength of their immune system. Many of those who have died were already in poor health.

Is the virus being transmitted from one person to another?

Human to human transmission has been confirmed by Chinas national health commission, and there have been human-to-human transmissions in the US and in Germany. As of 8 February, the death toll stands at 722 inside China, one in Hong Kong and one in the Philippines. Infections inside China stand at 31,161 and global infections have passed 280 in 28 countries. The mortality rate is 2%.

Two members of one family have been confirmed to have the virus in the UK, and a third person was diagnosed with it in Brighton, after more than 400 were tested and found negative. The Foreign Office has urged UK citizens to leave China if they can. Five new cases in France are British nationals, and British nationals are also among the 64 cases on a cruise liner off Japan.

The number of people to have contracted the virus could be far higher, as people with mild symptoms may not have been detected. Modelling byWorld Health Organization(WHO) experts at Imperial College London suggests there could be as many as 100,000 cases, with uncertainty putting the margins between 30,000 and 200,000.

Why is this worse than normal influenza, and how worried are the experts?

We dont yet know how dangerous the new coronavirus is, and we wont know until more data comes in. The mortality rate is around 2%. However, this is likely to be an overestimate since many more people are likely to have been infected by the virus but not suffered severe enough symptoms to attend hospital, and so have not been counted. For comparison, seasonal flu typically has a mortality rate below 1% and is thought to cause about400,000 deathseach year globally. Sars had a death rate of more than 10%.

Should I go to the doctor if I have a cough?

Unless you have recently travelled to China or been in contact with someone infected with the virus, then you should treat any cough or cold symptoms as normal. TheNHS advisesthat people should call 111 instead of visiting the GPs surgery as there is a risk they may infect others.

Is this a pandemic and should we panic?

Health experts are starting to say it could become a pandemic, but right now it falls short of what the WHO would consider to be one. A pandemic, in WHO terms, is the worldwide spread of a disease. Coronavirus cases have been confirmed in about 25 countries outside China, but by no means in all 195 on the WHOs list.

There is no need to panic. The spread of the virus outside China is worrying but not an unexpected development. The WHO has declared the outbreak to be a public health emergency of international concern, and says there is a window of opportunity to halt the spread of the disease. The key issues are how transmissible this new coronavirus is between people and what proportion become severely ill and end up in hospital. Often viruses that spread easily tend to have a milder impact.

Sarah BoseleyHealth editor andHannah Devlin

We typically think of viral content as a chain reaction: you share something with friends, they share it with their friends, and so on. In disease outbreak analysis, we can measure the transmission of an infection by looking at how many additional cases each infected person creates on average during each of these steps. We call this the reproduction number, and for coronavirus, we estimate its about 2 for a typical infected case in China. What about the reproduction number for online content? A couple of years ago, Facebook researchers looked at the most shared content on the platform from 2014 to 2016, including viral trends such as the ice-bucket challenge and putting an equals sign over your profile picture to support marriage equality.

Remarkably, there wasnt much difference in the transmission. Researchers found the reproduction number was about 2 for all of them. Remember, these were the most shared ideas on Facebook; the vast majority of online content is lucky to get even a single repost.

The scientific community is making huge progress in understanding the infection, but weve had to start at the bottom

To fully explain how viral content and viruses spread, we need to move away from the idea that outbreaks involve simple clockwork infections, passing along a chain from person to person to person until large numbers have been exposed. During the 2015 outbreak of the Mers coronavirus in South Korea, 82 out of 186 infections came from a single superspreading event in a hospital where an infected person was being treated. Its not yet clear how common such superspreading is in the current outbreak, but we do know that these kinds of events are how information goes viral online; most outbreaks on Twitter are dominated by a handful of individuals or media outlets, which are responsible for a large proportion of transmission. If you heard about snake flu, you might have told a couple of friends; meanwhile, newspaper headlines were telling millions.

When tackling disease outbreaks, health agencies often work to identify potential superspreading events, isolating infected individuals to prevent further transmission. However, this isnt the only way to stop an outbreak. As well as tracking down people who are infectious, its possible to target broader social interactions that might amplify transmission. For example, many cities in China have recently closed schools, which can be hotspots for respiratory infections.

Tech companies are now adopting similar approaches to tackle health misinformation. Last year, Pinterest announced it had rewired its search results to make it harder to find vaccine misinformation. It had struggled to remove the content completely the equivalent of finding all the cases during a disease outbreak so instead focused on reducing how many people might be exposed to harmful content. During the current outbreak, Google is attempting to reduce peoples susceptibility to misinformation by displaying links to reputable health sources when users search for information about the virus.

These combined approaches, which target different aspects of transmission, have long been used in disease control. By introducing analogous strategies online, we should have a better chance of effectively curbing harmful viral content.

Ensuring the public has the best possible health information is crucial during an outbreak. At best, misinformation can distract from important messages. At worst, it can lead to behaviour that amplifies disease transmission. The novelty of coronavirus makes the challenge even greater, because viral speculation can easily overwhelm the limited information we do have. The scientific community is already making huge progress in understanding the infection, but weve had to start at the bottom, without stacks of earlier research to stand on. When it comes to stopping the outbreak, well need ladders, not snakes.

Adam Kucharski an epidemiologist and the author of The Rules of Contagion: Why Things Spread and Why They Stop, published on 13 February

Read more:
Misinformation on the coronavirus might be the most contagious thing about it - The Guardian

Researchers May Have Found A Genetic Cause Of Infertility – mindbodygreen.com

The mechanism that controls the switch to meiosis has been a topic of scientific investigation for some time, and this breakthrough offers a unique look at a gene trigger that only sometimes becomes active. An important issue for reproductive medicine, researchers are excited for what this discovery could mean.

Knowledge of this process and the gene will be useful in providing a potential answer, but more answers could also mean more treatment options for people struggling with infertility.

"If it eventually becomes possible to control meiosis," said Ishiguro, "the benefits would be far-reaching for reproductive medicine, agricultural production, and even assisting rare species reproduction."

This research is still in early stages, with the announcement of the genetic discovery only being published this week. But it does provide a starting point for a whole new area of research in reproductive medicine going forward, that could result in even more new breakthroughs. Further studies will need to investigate the process of Meiosin in human subjects.

While we may not see this breakthrough being used in medicine anytime soon, it's exciting to know that it may help people in the future. If you're hoping to start a family and are worried about fertility, there's plenty of expert advice for boosting fertility that can be easily adopted.

Visit link:
Researchers May Have Found A Genetic Cause Of Infertility - mindbodygreen.com

Violin played by band on sinking Titanic on display in Branson, Mo. – KY3

"And the band played on..."

That well-known phrase is forever linked to the 1912 sinking of the Titanic as the band aboard the ill-fated ship played as passengers boarded the lifeboats.

Believe it or not a million-dollar artifact from that band that's survived for over a century will be on display at the Titanic Museum in Branson from February 8-June 15.

The museum is a reproduction of both the inside and outside of the legendary British passenger liner that sank in the early morning hours of April 15, 1912 after striking an iceberg on its maiden voyage in the North Atlantic Ocean. Of the estimated 2,224 passengers and crew aboard more than 1,500 died, making it one of the deadliest peacetime commercial marine disasters.

The Titanic museum in Branson and its sister-facility in Pigeon Forge, Tenn. have more than 400 artifacts from the actual ship but this one about to go on display in Branson is the most valuable and iconic.

"The most important piece of Titanic memorabilia in existence," said Andrew Aldridge of the Aldridge Auction Home in Great Britain, the firm that represents the anonymous owner of the piece.

"For us to have it now is incredible," added Paul Burns, the curator at the Branson Titanic Museum. "We're extremely lucky."

So what is it?

It's the actual violin played by bandleader Wallace Henry Hartley as his eight-piece band stood on the deck of the Titanic serenading passengers with hymns to try and calm them during the chaotic moments as they jumped on the lifeboats.

The band has become as much a part of the Titanic lore as the iceberg itself, recognized for their heroic gesture in the face of certain death. They've been an important part of any story of the Titanic's sad recounting, from books to movies, and the violin is an amazing survivor of that horrible night.

"If this violin could talk what incredible stories it could tell," Burns said.

Hartley, the bandleader who owned the violin, did not survive the sinking. His body was recovered two weeks after the disaster with a music case strapped to his body.

That case, which is also still around, is credited with why the violin was able to endure the cold, wet conditions and remain intact.

"When Wallace went into the water he had a valise, a big leather bag, and the violin was held within that valise," Aldridge explained. "That kept most of the water off it."

"Also the life preserver (Hartley was wearing) would have allowed the person's body to be two-thirds out of the water," Burns said of the Titanic's flotation devices. "So the violin really set out of the water inside the leather case."

Over the next century the violin went from Wallace's fiance to the Salvation Army to a music teacher to her student before the current anonymous owner bought it for the $1.7 million price tag.

The violin's authentication came from forensic testing that proved it had been in the waters of the North Atlantic and the presence of a metal plate on the front of the violin.

"On the fishplate (a flat piece of metal) it says, 'To Wallace on the occasion of our engagement. From Maria,'" Aldridge said. "And Maria Robinson was Wallace's fiance."

As you would expect the violin is handled like a baby, kept in a climate-controlled environment on a specially-made acrillic stand.

"When we place it on the stand we will take the weight completely off the violin so it will not rest on its own weight," Burns said in explaining that the wood portion of the violin is the most critical part to keep from aging.

Mary Kellogg, the co-owner and COO of the Titanic Museum, estimates that the violin is worth even more now since it is a one-of-a-kind item, and it's strange when you consider that this small musical instrument is worth much more than the million-dollar Grand Staircase that the museum recreated from the original Titanic that includes gold railings and an ornate ceiling and chandelier.

But the real reason the violin is the most valuable of all the Titanic artifacts is not what it is, but what it represents.

It's all that's left of a tragic sacrifice by eight men.

"The most selfless act you can imagine," Aldridge said of their heroics. "They're giving their life to comfort and soothe those around them."

"This represents all that," Burns said, pointing to the violin. "It's the most precious. What it represents, the icon, the human interest side of this, is the key to Titanic living on."

The violin will be on display in Branson from February 8-June 15. The museum is open daily at 9 a.m. and reservations are strongly suggested, especially during spring break times.

Original post:
Violin played by band on sinking Titanic on display in Branson, Mo. - KY3

With Roundup-cancer settlement looming, activists revive conspiracy claim that glyphosate surfactants threaten human health – Genetic Literacy Project

Whats the most dangerous global health threat, jeopardizing the welfare of possibly millions of people? Forgive yourself if you answered coronavirus. A trip through cyberspace has identified the real menace: glyphosate, the active ingredient in Bayers weed killer Roundup.

The herbicide is widely regarded by scientists as a highly effective, low-toxicity pesticide used by farmers and consumers worldwide to clear farms and home gardens of pesky weeds. But using a tsunami of TV commercials designed to entice anyone with cancer to sign up for the lets sue Bayer lottery, a handful of law firms has launched a legal crusade alleging the chemical giant and its corrupt enablersread the 15 most influential regulatory agencies in the world, including the European Food Safety Authority, Health Canada and the EPA that say glyphosate is relatively harmlesshave been in cahoots to cover up the dangers of Roundup.

What are these alleged dangers? According to the law offices of Wallace & Graham, one of the dozens of ambulance-chasing firms angling for new plaintiffs, glyphosate can cause, among other things, skin irritation, nausea, liver damage, diabetes, kidney disease, Parkinsons disease, breathing problems, Lou Gehrigs disease, sterility in men, and, worst of all, cancer.

Killer surfactants!

Now the killer-glyphosate narrative has taken a new twist. Although the EPA on January 30 reaffirmed its long-time finding that glyphosate isnt carcinogenic, some anti-pesticide activists have seized on a recent study to argue that other ingredients in Roundup may have cancer-causing properties as well. Their allegation highlights a decades-long controversy surrounding chemicals called surfactants, the non-toxic soapy substances that enhance glyphosates ability to spread through plants. Surfactants are also found in products ranging from laundry detergents to organic pesticides.

Promotion of the study by a key publicist working on behalf of the glyphosate tort teamformer journalist Carey Gillam, director of research at the anti-GMO outfit US Right to Know (USRTK)adds a new wrinkle to the plaintiffs strategy to push Bayer to settle 75,000 or more claims for as much as $10 billion, which could happen any day now. While Gillam and other critics of glyphosate may see the study as a boon to the legal action, their coverage inadvertently exposes the limitations of this and similar studies, and highlights crippling flaws in the allegation that Roundup causes cancer.

Writing in UK newspaper The Guardian on January 23, Gillam outlined the latest study and its significance to the debate over the supposed health risks of Roundup exposure:

Tests by a US government agency on common weedkilling products made with the chemical glyphosate have found some formulations sold to the public . are damaging to human DNA. But the government scientists at the National Toxicology Program (NTP) say the danger probably lies with added ingredients in the products not glyphosate.

. The results, which are preliminary, showed . genotoxic effects with glyphosate-based formulations (GBFs) that include chemicals called surfactants . plus the weedkilling chemicals diquat dibromide, mesotrione and metolachlor . Monsantos German owner Bayer AG is currently mired in litigation brought by tens of thousands of cancer patients who claim exposure to Monsantos Roundup and other similar glyphosate-based formulated products made by Monsanto caused their cancers .

The US Environmental Protection Agency (EPA) backs the safety of glyphosate but has not required in-depth carcinogenicity testing of the full glyphosate-based formulated product, focusing research requirements on glyphosate alone.

Dissecting incomplete cell-culture research

The study, conducted by scientists at the National Institute of Environmental Health Sciences (NIEHS), is an example of an in-vitro or cell-culture study, in which isolated cells are exposed to a chemical, often at abnormally high doses, to see what happens. Its not clear which study Gillam was referring to since she didnt link to it, though its probably a series of preliminary September 2019 experiments from the National Toxicology Program (NTP).

The study has yet to appear in a scientific journal, and therein lies the first problem, according to two experts GLP contacted. I think it is dangerous to base any conclusions on data that have not been peer reviewed. There is not enough info in that [NTP study], wroteTrevor Charles, a microbiologist at the University of Waterloo in Ontario, in an email. Biologist Mary Mangan offered an additional word of caution:

Typically, Carey Gillam has omitted key details of the work that would be needed to understand the science. We dont know what kinds of test were done, on what cell systems, or if dosages reflect real-world exposures. Further, we cannot know if any of the other compounds that are handwaved about here are unique to glyphosate based formulations.

Its also likely that users have access to many other formulations from other world-wide suppliers. Theres no reason to suspect that surfactants are limited to one product line. The only thing that seems clear from Gillams item is that glyphosate itself [is] not genotoxic or harmful to cells in this testing. Of course, as this work is not peer-reviewed and published, its impossible to draw conclusions from this apparently preliminary disclosure.

Cell-culture studies shouldnt be dismissed out of hand. The data they generate can be useful. But we need to remember these experiments give . us little idea about the relevance [of Roundup exposure] when it comes to food residues, cell biologist Iida Ruishalme explained in 2016. This is because cells in a laboratory dont react to surfactants the way humans do.

They arent protected by your skin or your digestive tract or whatever [organ they come from], Mangan added. So exposing them to soap screws up their membranes and kills them. Its not necessarily that the test compound is genotoxic or mutagenic. In fact, this sort of research is so nebulous, scientists can and have argued that glyphosate and other ingredients in Roundup not only cause cancer but can be used to treat cancer, as Ive noted in previous GLP articles.

The science of surfactants

The concern that other Roundup ingredient besides glyphosate could be toxic goes back to at least 1997, when USDA researchers noted that . there does not appear to be adequate data to develop quantitative risk assessments of the surfactants. Several cell-culture and animal experiments since then have suggested that these chemicals may pose dangers, but none of these conclusions has gained much traction in the broader scientific community, for the reasons discussed above and because high-quality epidemiological studies show that farmers (those with the highest exposure to Roundup) do not face a higher cancer risk compared to the rest of the population.

Setting aside the epidemiology for a moment, the research specifically on surfactants tells a much different story than the tale Gillam spun in her Guardian piece. A review published in 2000, for instance, examined all the research related to the potential health effects of glyphosate, its breakdown product aminomethylphosphonic acid (AMPA) and the surfactant polyethoxylated tallow amine (POEA). After surveying the literature, the authors concluded:

[T]he use of Roundup herbicide does not result in adverse effects on development, reproduction, or endocrine systems in humans and other mammals. For purposes of risk assessment, no-observed-adverse-effect levels (NOAELs) were identified for all subchronic, chronic, developmental, and reproduction studies with glyphosate, AMPA, and POEA . [U]nder present and expected conditions of use, Roundup herbicide does not pose a health risk to humans.

This conclusion was confirmed by a 2009 EPA risk assessment of alkyl amine polyalkoxylates, the class of surfactants POEA belongs to:

There is no evidence that alkyl amine polyalkoxylates are neurotoxic, mutagenic, or clastogenic [able to damage chromosomes] . Based on these risk assessments, EPA concludes that there is a reasonable certainty that no harm will result to the general population .

In April 2017, Health Canada similarly concluded that [n]o risk of concerns to human health or the environment were identified provided that products contained no more than 20% POEA by weight and proposed label directions . are followed. Finally, a team of Bayer researchers published a study in October 2019 examining the health effects of exposure to polyethoxylated tallow amine (abbreviated as POE-T).

Repeated dosing of rats with POE-T produced gastrointestinal effects but no systemic effect on organ systems. POE-T was not genotoxic and had no effect on embryo-fetal development or reproduction, they wrote. After calculating the occupational exposure of farmers and exposure through food (how most people are exposed to the surfactant), the authors concluded:

Based on the results of the occupational and food risk assessments, it is concluded that there are no significant human health issues associated with the use of POE-T as a surfactant in glyphosate products.

Some skeptical readers may balk at this conclusion since it came from Bayer, which obviously has an interest in vindicating its flagship weed killer. Thats a reasonable objection, but the data and methodology for the company-conducted research came from previously published studies, as well as the World Health Organization, European Food Safety Authority and the EPA. More importantly, Bayers conclusion matches that of dozens of other studies that have examined surfactants used in Roundup, most notably the assessments from the EPA and Health Canada.

Angling for favorable settlement terms?

Science be damned, anti-pesticide activists have attempted to muddy the waters, pushing the surfactants-might-cause-cancer allegation to demonize what is otherwise considered a safe, effective herbicide. Organic industry-funded agricultural economist Charles Benbook, for instance, recently warned that concerns about surfactants could influence the litigation, without acknowledging the science that contradicts his case.

Its the surfactants that are carrying the glyphosate first through the skin and inside the body, and then inside of cells where damage can be done to DNA, Benbrook told Business Insider in 2019:

In Europe, Benbrook noted, surfactant chemicals have been made less toxic for consumers. In the US, however, Monsanto has not changed Roundup formulas in the same way. When juries learn that Monsanto is making a product thats at least 10 times, maybe 100 times safer all across Europe? he said.

Thats not acceptable. Thats one of the reasons that I think we can expect a continuation of these mammoth punitive damage awards .

Gillam took this same approach in her Guardian piece, focusing on a series of quotes from the early 2000s, in which several Monsanto researchers, reflecting the caution inherent in all research, seemed to acknowledge they couldnt confirm the safety of the added ingredients in Roundup. You cannot say that Roundup is not a carcinogen, one scientist wrote in an email in 2003. We have not done the necessary testing on the formulation to make that statement.

As is her wont to manipulate quotes to serve her ideological interests, Gillam left out the second part of the statement, which provides critical context: We can make that statement about glyphosate and can infer that there is no reason to believe that Roundup would cause cancer, the scientist wrote.

Another company scientist, according to Gillam, issued a similar warning in 2010: With regards to the carcinogenicity of our formulations we dont have such testing on them directly. Again, the second part of the quote, which Gilliam tellingly left out, contextualizes the situation: . but we do have such testing on the glyphosate component and some extensive [toxicology] testing on the surfactant. Since the glyphosate formulations are simply a blend of these components, I think we can address these questions in a confident manner. Both statements reflect the conclusions of the research on surfactants discussed above.

Erin Brockovich 2.0

The plaintiffs in the estimated 75,000+ lawsuits alleging that Roundup is carcinogenic have anchored their claim to a heavily criticized 2015 hazard assessment issued by the International Agency for Research on Cancer (IARC), which concluded that glyphosate is a probable carcinogen. That put glyphosate in the same toxicity category as red meat, drinking hot beverages, and going to the hairdresser or barber, but not in the far more dangerous category which includes red wine or coffee. Although scientifically suspect to say the least, Benbrook and Gillams claim that surfactants are potential killers has helped the plaintiffs sell the conspiracy narrative to juries and judges that Bayer and sympathetic EPA regulators are suppressing inconvenient science to protect industry profit.

The surfactant argument was especially favored by Tim Litzenburg, one of the attorneys in the Bayer litigation who was recently fired by his firm and charged by the US government for allegedly trying to extort a chemical company that manufacturers surfactants for Roundup. Gillam had worked with Litzenburg to promote the surfactant-cancer link before he was charged.

The messy history of this scientifically dubious claim has not deterred the other lawyers in the glyphosate class action. Attorneys in the second trial (only three cases, all in California, have reached a courtroom so far) likewise told the judge, Plaintiff intends to introduce even more evidence . that Roundup is more dangerous than glyphosate because surfactants increase the danger of glyphosate exponentially. The jury in that trial awarded the plaintiff $80 million, though it was reduced to $25 million. Baum Hedlund, one of the primary law firms involved in the litigation, previously cited the statements from Monsanto scientists as evidence that once again demonstrates suspicions by Monsanto that it is biologically plausible for the formulated product to promote tumors.

This is compelling storytelling, reminiscent of films like Erin Brockovich and Conspiracy, but the science behind the lawyers claims is thin at best. Yet, the scary rhetoric could very well push Bayer towards a settlement for fear that other juries will be even more outraged when they hear that a callous corporation allegedly ignored warnings from its own scientists.

There are several important takeaways from the recent controversy surrounding the still unreleased NTP surfactant research. First, the data and conclusions have not been reviewed by other experts and published in a journal, making it reckless for Gillam or anyone else to draw a conclusion from the results. But even after the results are published, they will only add to a collection of contradictory and inconclusive cell-culture experiments on Roundup, which even anti-GMO news outlet GM watch has acknowledged are problematic.

[T]he NTP seems to have simply added to a large body of data characterized by conflicting results. And crucially, the NTPs results do not disprove those of the numerous other studies that reached opposite conclusions.

If anything, the willingness of activists and tort lawyers to trumpet the results of what appears to be relatively weak research illustrates the flaws in their case against Bayer, especially since there are hundreds of higher-quality studies and regulatory reviews of Roundup available.

Theres no way to know how the legal battle will play out, although one thing can be said for certain about this whole affair: The narrative of underdog cancer victims and their lawyers unmasking corporate villains isnt backed up by the evidence. Until more conclusive data come along, theres no reason to think Roundup or any of its individual ingredients cause cancer.

Cameron J. English is the GLPs senior agricultural genetics and special projects editor. He is a science writer and podcast host. BIO. Follow him on Twitter @camjenglish

More:
With Roundup-cancer settlement looming, activists revive conspiracy claim that glyphosate surfactants threaten human health - Genetic Literacy Project

Researchers identify roots of childhood asthma – European Biotechnology

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

See the original post:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? – InvestorsObserver

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Originally posted here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE – Simply Wall St

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, well use ROE to better understand Avecho Biotechnology Limited (ASX:AVE).

Over the last twelve months Avecho Biotechnology has recorded a ROE of 2.5%. One way to conceptualize this, is that for each A$1 of shareholders equity it has, the company made A$0.03 in profit.

Check out our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Avecho Biotechnology:

2.5% = AU$158k AU$6.2m (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders equity is to subtract the companys total liabilities from the total assets.

Return on Equity measures a companys profitability against the profit it has kept for the business (plus any capital injections). The return is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Avecho Biotechnology has a lower ROE than the average (7.7%) in the Pharmaceuticals industry.

That certainly isnt ideal. Wed prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Most companies need money from somewhere to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Avecho Biotechnology is free of net debt, which is a positive for shareholders. Without a doubt it has a fairly low ROE, but that isnt so bad when you consider it has no debt. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities.

Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt.

But when a business is high quality, the market often bids it up to a price that reflects this. It is important to consider other factors, such as future profit growth and how much investment is required going forward. Check the past profit growth by Avecho Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Link:
Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE - Simply Wall St

Here’s Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today – Motley Fool

What happened

Shares of Inovio Pharmaceuticals (NASDAQ:INO) and Vir Biotechnology (NASDAQ:VIR), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (NASDAQ:GILD) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

Image source: Getty Images.

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

View original post here:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today - Motley Fool

Improving food production with agricultural technology and plant biotechnology – The John Innes Centre

Learn how to address challenges in growing, harvesting, and processingfood and build your knowledge of food production challenges and technology with this FutureLearn online course for 16-19 year olds studyingbiology.

Are you inspired to join the next generation of scientists and tackle challenges in food security?

On this course, you will get access to innovative research solutions that address some of the biggest issues in food, agriculture, and plant biotechnology.

You will become more familiar with the journey plants take, from crops in the field to food on your plate. You will explore the importance of scientific research in food security and discover the new technologies that are transforming agriculture.

The course starts on 2 March 2020 and mentors will be online to interact with learners until 22 March 2020. Participants will be able to join the course up until 4 May 2020.

By the end of the course, youll be able to

Read more:
Improving food production with agricultural technology and plant biotechnology - The John Innes Centre

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts…

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

See the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

Where Is The Biotech Market Heading? – CIO Applications

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

See the original post here:
Where Is The Biotech Market Heading? - CIO Applications

Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech News

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

See the original post here:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service – Yahoo Finance

MIRAMAR, Fla., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (GNBT) is pleased to announce that the companys subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has begun shipping Excellagen to the Indian Health Services in Arizona, following approval by the value added committee (VAC). Native American Indian adults are almost three times more likely to have diabetes and 2.5 times more likely to die from the complications of diabetes than the majority of other Americans. Excellagen wound conforming gel matrix is FDA cleared to manage 17 types of wounds including diabetic foot ulcers and venous leg ulcers, which are prevalent in the diabetic patient population. The Indian Health Service (IHS), an agency within the U.S. Department of Health and Human Services, provides care to over 2.2 million Native Americans in more than 560 recognized tribes across the country.

Anthony J. Dolisi, President and Chief Executive Officer of Olaregen said, We are excited that Excellagen has been approved by the Indian Health Services Value Added Committee, which not only enables us to begin selling Excellagen in Arizona, but which also opens the door to VAC approval across the IHS. We continue to make gains in the VA hospitals, where Excellagen is achieving some fantastic results for veterans who are dealing with hard to heal wounds, and we expect to achieve a national footprint by the end of the year. Additionally, we have begun the VAC approval process in the private sector and have just signed a new hospital in Texas.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization and medical device companies with new and approved products.

About Olaregen TherapeutixOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care.Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications.Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen's initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex's mission is to become a significant force in regenerative medicine and advance the science of healing.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Story continues

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

Follow this link:
Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen to the Arizona Indian Health Service - Yahoo Finance

Generex Biotechnology Appoints Independent Director Carol Nacy, PhD to the NuGenerex Immuno-Oncology Board of DirectorsBiotechnology industry veteran…

MIRAMAR, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation(www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Dr. Carol Nacy, PhD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Nacy is a founder and the Chief Executive Officer of Sequella, Inc., a privately held pharmaceutical company that discovers and develops new and more effective treatments for life threatening infectious diseases. Previously, Dr. Nacy was Executive Vice President and Chief Scientific Officer at EntreMed,Inc. from 1993 through its successful public offering in June 1996. Prior to her career in biotechnology, Dr. Nacy worked for 17 years at the Walter Reed Army Institute of Research in Washington, DC, where she studied tropical infectious diseases. She has published over 165 scientific papers to date.

Dr. Nacy has a long and successful career in infectious disease research and has been widely recognized for her achievements in the biotechnology industry. She was singled out as a Top 50 Innovator in the U.S. by Inc. Magazine in 2002, named Entrepreneur of the Year by Women in BIO in 2004, the state of Maryland named her in its Top 100 Business Women in 2005, and the Washington Business Journal named her as a top 25 female executive in the Washington DC metropolitan area in 2005. In 2006, she received a National Leadership Award in Healthcare from the National Urban Technology Center in New York City, and in 2007 she was honored with a Special Outstanding Achievement Award for Clinical Trials by Women in BIO. In 2009 she was awarded the Humanitarian Award, Hope is a Vaccine, by the Global Alliance for Immunization against Aids (GAIA) for her work to create new drugs for TB. She is an Editor for the American Academy of Microbiology journal, mBio, and an adjunct faculty member of the Department of Tropical Diseases at the George Washington University, Washington, DC. She earned her A.B., M.S., and Ph.D. degrees from the Catholic University of America in Washington, DC, which awarded Dr. Nacy with a Lifetime Achievement Award in Science.

Dr. Nacy commented on her appointment to the NGIO Board, The field of cancer immunotherapy has finally come into its own, and I am thrilled to be part of NuGenerex Immuno-Oncology. I am looking forward to working with the company to bring important new therapies to patients in need.

We are proud to welcome Dr. Nacy to our Board of Directors for NGIO, said Joseph Moscato, President & CEO of Generex Biotechnology. She is an innovator and a leader in the field of infectious disease and vaccine development, bringing together science, business, and policy to make a positive impact on global health. Her knowledge and experience will be highly valuable as we build NuGenerex Immuno-Oncology.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato646-599-6222

Todd Falls1-800-391-6755 Extension 222investor@generex.com

View original post here:
Generex Biotechnology Appoints Independent Director Carol Nacy, PhD to the NuGenerex Immuno-Oncology Board of DirectorsBiotechnology industry veteran...